CE Education
How I Approach MDS Diagnosis and Risk Assessment
Hetty E. Carraway, MD, MBA, FACP |
Clinical Commentaries
Experts Discuss DACOTA Phase 3 Trial of Decitabine versus Hydroxyurea for Advanced Proliferative CMML
Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD |
CE Education
Management of Hypomethylating Agent (HMA) Failure in Myelodysplastic Syndromes (MDS)
Jamile M. Shammo, MD, FASCP, FACP |
CE Education
Updates in MDS: A Special Edition on Higher-risk Disease
Mikkael S. Sekeres, MD, MS |
CE Education
Chronic Anemia in MDS: Focus on Newer Strategies for ESA-refractory or Relapsed Patients
David Sallman, MD |
Clinical Case Snapshots
78-year-old man with sideroblastic MDS and ESA failure
David Sallman, MD |
CE Education
Treatment Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Vijaya Raj Bhatt, MD; Mikkael A. Sekeres, MD |
Frequently Asked Questions
What are the key investigational studies to keep an eye on in higher-risk MDS patients in the post-AZA setting?
Rami S. Komrokji, MD |
Frequently Asked Questions
As a community practitioner, what key factors do I need to remember in determining treatment options for my patients?
Rami S. Komrokji, MD
View all FAQs |
Clinical Pearls Podcasts
How will ASTX727 be used in clinic?
Guillermo Garcia-Manero, MD |
